Mizuho rated Buy THRESHOLD PHARMACEUT (NASDAQ: THLD) on 04/02/2012, when the stock price was $8.46. Since then, THRESHOLD PHARMACEUT has lost 34.99% as of 06/18/2013's recent price of $5.50.
If you would have followed this Mizuho's recommendation on THLD, you would have lost 34.98% of your investment in 442 days.

Threshold is focused on the discovery, development, and commercialization of small molecule therapeutics based on `Metabolic Targeting.` This approach targets abnormal glucose metabolism - a fundamental property of most solid tumors and other diseases. The company's initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.

Mizuho

Marked as spam